Emerging Company Profile
Concarlo: targeting proliferation and resistance in one go
SUNY Downstate spinout takes aim at metastatic breast cancer by targeting p27
By targeting p27, SUNY Downstate spinout Concarlo simultaneously takes aim at mechanisms of proliferation and resistance in cancer, starting with metastatic breast cancer.
Aug 28, 2020 | 9:42 PM GMT
Concarlo is developing targeted therapies